Amy A. Hassan

Hematology

2280 Gulf Fwy S
League City, TX 77573

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.

Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.

Journal: JAMA network open

Published: May 11, 2023

Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.

Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 14, 2022

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.

Journal: NPJ breast cancer

Published: September 04, 2022

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Journal: Breast cancer research and treatment

Published: December 13, 2021

Diffuse Large B-Cell Lymphoma at the Site of a Herpes Zoster Scar.

Diffuse Large B-Cell Lymphoma at the Site of a Herpes Zoster Scar.

Journal: World journal of oncology

Published: June 14, 2012

Showing 1-5 of 5

Last Updated: 09/26/2026